Is decreased libido associated with the use of HMG-CoA-reductase inhibitors?
- PMID: 15327593
- PMCID: PMC1884568
- DOI: 10.1111/j.1365-2125.2004.02128.x
Is decreased libido associated with the use of HMG-CoA-reductase inhibitors?
Abstract
Aims and methods: To describe patients with decreased libido during use of a HMG-CoA-reductase-inhibitor, and to discuss causality and pharmacological hypotheses for this association by analysis of the adverse drug reactions (ADR) database of the Netherlands Pharmacovigilance Centre Lareb.
Results: Eight patients were identified as having decreased libido during use of statins. In two of these cases testosterone levels were determined and appeared to be decreased.
Conclusion: Decreased libido is a probable adverse drug reaction of HMG-CoA-reductase-inhibitors and is reversible. The ADR may be caused by low serum testosterone levels, mainly due to intracellular cholesterol depletion.
Similar articles
-
HMG-CoA-reductase inhibitors and neuropathy: reports to the Netherlands Pharmacovigilance Centre.Neth J Med. 2006 Oct;64(9):334-8. Neth J Med. 2006. PMID: 17057271
-
The HMG Co-A reductase inhibitors ('statins') and myotoxic effects.S Afr Med J. 2002 Aug;92(8):596-7. S Afr Med J. 2002. PMID: 12244613 No abstract available.
-
Lichenoid drug eruption with HMG-CoA reductase inhibitors (fluvastatin and lovastatin).Acta Derm Venereol. 2004;84(3):229-30. doi: 10.1080/00015550310006851. Acta Derm Venereol. 2004. PMID: 15202842 No abstract available.
-
[Cardiovascular pharmacology (VIII). The role of HMG CoA reductase inhibitors in the current treatment of hyperlipidemias].Rev Esp Cardiol. 1995 Jan;48(1):59-65. Rev Esp Cardiol. 1995. PMID: 7878284 Review. Spanish. No abstract available.
-
[High therapeutic effect and safety of fluvastatin].Pharm Unserer Zeit. 2003;32(6):516-7. doi: 10.1002/pauz.200390134. Pharm Unserer Zeit. 2003. PMID: 14639833 Review. German. No abstract available.
Cited by
-
Neuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management.CNS Drugs. 2014 Mar;28(3):249-72. doi: 10.1007/s40263-013-0135-1. CNS Drugs. 2014. PMID: 24435290 Review.
-
HMG CoA reductase inhibitors and impotence: two case series from the Spanish and French drug monitoring systems.Drug Saf. 2006;29(2):143-9. doi: 10.2165/00002018-200629020-00004. Drug Saf. 2006. PMID: 16454541
-
Statins and male sexual health: a retrospective cohort analysis.J Sex Med. 2015 Jan;12(1):158-67. doi: 10.1111/jsm.12745. Epub 2014 Nov 25. J Sex Med. 2015. PMID: 25421152 Free PMC article.
-
Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism.Am J Cardiovasc Drugs. 2008;8(6):373-418. doi: 10.2165/0129784-200808060-00004. Am J Cardiovasc Drugs. 2008. PMID: 19159124 Free PMC article. Review.
-
Do statins lower testosterone and does it matter?BMC Med. 2013 Feb 28;11:58. doi: 10.1186/1741-7015-11-58. BMC Med. 2013. PMID: 23448188 Free PMC article.
References
-
- Rizvi K, Hampson JP, Harvey JN. Do lipid-lowering drugs cause erectile dysfunction? A systematic review. Fam Pract. 2002;19:95–8. - PubMed
-
- Crenshaw TL, Goldberg PJ. Testosterone in men. In: Crenshaw TL, Goldberg PJ, editors. Sexual Pharmacology. New York: WW Norton Co.; 1996. pp. 115–28.
-
- Griffin JE, Wilson JD. Disorders of the testes. In: Braunwald E, Fauci AS, Kapser DL, Hauser SL, Longo DL, Jameson JL, editors. Harrison's Principles of Internal Medicine. 15. New York: McGraw-Hill Medical Publishing Division; 2001. pp. 2143–54.
-
- Ginsberg HN, Golberg IJ. Disorders of intermediary metabolism. In: Braunwald E, Fauci AS, Kapser DL, Hauser SL, Longo DL, Jameson JL, editors. Harrison's Principles of Internal Medicine. 15. New York: McGraw-Hill Medical Publishing Division; 2001. pp. 2245–57.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials